Tweedy Browne Co LLC Decreases Stock Position in Kenvue Inc. (NYSE:KVUE)

Tweedy Browne Co LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 356,796 shares of the company’s stock after selling 26,410 shares during the period. Kenvue makes up approximately 0.5% of Tweedy Browne Co LLC’s investment portfolio, making the stock its 24th biggest position. Tweedy Browne Co LLC’s holdings in Kenvue were worth $7,618,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Grove Bank & Trust boosted its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. boosted its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 1.1 %

NYSE:KVUE opened at $23.97 on Tuesday. The company has a market cap of $45.80 billion, a price-to-earnings ratio of 45.22, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $22.38 and a 200-day simple moving average of $22.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.42%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the subject of several research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Barclays boosted their price objective on Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 27th. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Finally, Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.